Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer

Figure 3

Effects of anti-estrogenic (A) and ERβ agonist (B) treatment on the proliferation rates of MCF7 and MCF7-ERβ1 expressing cells. Crystal violet assays were used to determine proliferation rates following indicated treatments for 12 days. P-values < 0.05 were considered to be statistically significant. *Denotes significant difference between indicated treatment and vehicle control treated cells and # between indicated treatment and estrogen treated cells.

Back to article page
\